A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > COMMENTARY
COMMENTARY
- GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
- Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
- Japan's Most Admired Pharma Companies in 2010
April 4, 2011
- Will New Disclosure GL Promote Industry-Academia Alliances?
March 28, 2011
- Use of Generics by Welfare Recipients
March 7, 2011
- Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
February 21, 2011
- Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
February 21, 2011
- Recent Topics in Promising Anticancer Therapeutics
January 17, 2011
- Development Race for Oral Anticoagulants Entering Final Stretch
October 11, 2010
- How to Eliminate Concerns about Safety of Liovel
October 4, 2010
- Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
September 20, 2010
- Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
September 13, 2010
- Prior Assessment System Is One Step Forward to Quicker NDA Review
August 2, 2010
- Industry Needs to Form Consensus on Premium with Med. Institutions
July 26, 2010
- Japan Should Promote Personalized Cancer Treatment
July 26, 2010
- METI Reports on “Patent Box”Taxation System in Its Vision 2010
July 5, 2010
- How Will Generics-Only Companies Will Compete with Major New Entrants?
June 28, 2010
- Mr Hasegawa Calls For Cooperation with Asian Countries
June 21, 2010
- PMDA Consultation for Clinical Drug Development in Japan
April 26, 2010
- Taiyo Needs to Restart from Scratch
April 19, 2010
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…